Danish industrial biotechnology company 21st.BIO has filed an EU Novel Food application for its precision-fermented milk protein BLG Essential+ (bovine beta-lactoglobulin), while calling for a faster regulatory pathway to help European biotechnology companies establish production and sell their ingredients closer to home.
The company wants faster, predictable approvals for proteins made using established production platforms. Alongside the submission, 21st.BIO argued that Europe needs a more predictable route to market for well-characterized proteins that match those found in nature and are manufactured using production platforms with an established safety record.
Thomas G. Schmidt, Co-founder & CEO of 21st.BIO: “What Europe still needs is a home market that allows industrially proven technology to move from laboratories into fermentation factories built in Europe. A predictable, science-based route to market can strengthen food resilience, attract industrial investment and ensure that European innovation is commercialized in Europe.”
BLG Essential+ is produced using Aspergillus oryzae, a microorganism with a long history in Japanese food fermentation, including soy sauce and miso. According to 21st.BIO, its production platform builds on decades of development by Novonesis and further work by its own team. The company cited a 2025 peer-reviewed study in Applied Microbiology and Biotechnology describing the strain lineage as the first mycotoxin-free A. oryzae lineage for industrial production of alternative and novel proteins.